Trevi Therapeutics Announces Pricing of $50 Million Underwritten OfferingNew Haven, Conn., December 16, 2024 – Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy, Haduvio ™ (oral

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read TKO Group’s 8K filing here.

About TKO Group

(Get Free Report)

TKO Group Holdings, Inc operates as a sports and entertainment company. The company produces and licenses live events, television programs, and long-form and short-form content, reality series, and other filmed entertainment on digital and linear channels and via pay-per-view. It is involved in the merchandising of video games, apparel, equipment, trading cards, memorabilia, digital goods, and toys, as well as sale of travel packages and tickets.

See Also